11 assets in Lymphatic System Disorder

Therapeutic assets addressing Lymphatic System Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bendamustine Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P2	B (60)
Cyclophosphamide Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P2	B (60)
Ibrutinib Lymphatic System Disorder	Oncternal Therapeutics, Inc	P3	B (60)
Zilovertamab Lymphatic System Disorder	Oncternal Therapeutics, Inc	P3	B (60)
Brentuximab Vedotin Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P2	B (57)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Lymphatic System Disorder	City of Hope Medical Center	P2	CCC (53)
Sepantronium Lymphatic System Disorder	Cothera Bioscience, Inc	P2	CCC (53)
Atlcar.Cd30.Ccr4 Cells Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Fludarabine Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
ic9-car19 t cells Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Rimiducid Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)